to further develop Episalvan as a new treatment for a hereditary skin disorder called Epidermolysis Bullosa in both Europe and the U.S.

Amryt’s earlier-stage products are focussed on developing novel, next-generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there are high unmet medical needs. These include acromegaly and Cushing's disease.